SCHEMBL24487771

SCHEMBL24487771

COC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](F)[C@@H]1O

nearest known ligand 0.82

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ AHCY P23526 8/20 0.82
▸ ADORA3 P0DMS8 5/20 0.66
▸ ADORA2B P29275 3/20 0.66
▸ HSP90B1 P14625 3/20 0.65
▸ ADORA2A P29274 2/20 0.62
▸ TSHR P16473 2/20 0.62
▸ LMNA P02545 1/20 0.62
▸ THRB P10828 1/20 0.62
▸ BLM P54132 1/20 0.62
▸ KMT2A Q03164 1/20 0.62
▸ HSP90AA1 P07900 1/20 0.62
▸ ADORA1 P30542 1/20 0.62
▸ HIF1A Q16665 1/20 0.61
▸ TMEM97 Q5BJF2 1/20 0.61
▸ SIGMAR1 Q99720 1/20 0.61
▸ CYP2C19 P33261 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20579582 0.90 AHCY (1.00) AHCYADORA3ADORA2BHSP90B1ADORA2A
SCHEMBL26554188 0.89 AHCY (0.72) AHCYADORA3ADORA2BHSP90B1ADORA2A
SCHEMBL13964644 0.87 AHCY (0.80) AHCYADORA3ADORA2BHSP90B1ADORA2A
SCHEMBL19189442 0.87 AHCY (0.80) AHCYADORA3ADORA2BHSP90B1ADORA2A
SCHEMBL19189542 0.87 AHCY (0.80) AHCYADORA3ADORA2BHSP90B1ADORA2A
SCHEMBL19190163 0.87 AHCY (0.80) AHCYADORA3ADORA2BHSP90B1ADORA2A
SCHEMBL13974288 0.87 AHCY (0.80) AHCYADORA3ADORA2BHSP90B1ADORA2A
SCHEMBL18801554 0.87 AHCY (0.80) AHCYADORA3ADORA2BHSP90B1ADORA2A
SCHEMBL12154738 0.87 AHCY (0.80) AHCYADORA3ADORA2BHSP90B1ADORA2A
SCHEMBL18801543 0.87 AHCY (0.80) AHCYADORA3ADORA2BHSP90B1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365970-A1 Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof ALIGOS THERAPEUTICS, INC. (US) 2023-11-16 — — US disclosed
US-20230365970-A1 Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof ALIGOS THERAPEUTICS, INC. (US) 2023-11-16 — — US disclosed
US-20230332153-A1 Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof ALIGOS THERAPEUTICS, INC. (US) 2023-10-19 — — US disclosed
US-20230332153-A1 Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof ALIGOS THERAPEUTICS, INC. (US) 2023-10-19 — — US disclosed
US-11549110-B2 Modified short interfering nucleic acid (siNA) molecules and uses thereof ALIGOS THERAPEUTICS, INC. (US) 2023-01-10 — — US disclosed
US-20220177888-A1 Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof ALIGOS THERAPEUTICS, INC. (US) 2022-06-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365970-A1 Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof NSUN2, SNRPA, SNRPF AHCY 3101/4885ADORA3 1358/4885ADORA2B 837/4885
US-11549110-B2 Modified short interfering nucleic acid (siNA) molecules and uses thereof NSUN2, SNRPA, SNRPF AHCY 3101/4885ADORA3 1358/4885ADORA2B 837/4885
US-20220177888-A1 Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof NSUN2, SNRPA, SNRPF AHCY 3101/4885ADORA3 1358/4885ADORA2B 837/4885
US-20230332153-A1 Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof NSUN2, SNRPA, SNRPF AHCY 3101/4885ADORA3 1358/4885ADORA2B 837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback